The best stocks to buy for October 2022? 2 health titles in a nutshell


The health sector is growing at an unprecedented rate, and healthcare inventory are poised to take advantage of this growth. It matters because healthcare companies are developing innovative new treatments and technologies that are transforming the way we take care of our health. As a result, health actions offer stock Exchange investors the opportunity to participate in this growth and benefit from the success of companies in the healthcare sector.

Additionally, healthcare stocks are generally a safer investment that can offer long-term growth potential. When choosing healthcare stocks, it is important to consider financial stability, future prospects and the company’s management team. Additionally, healthcare stocks offer investors the opportunity to make a profitable investment in an industry that is making a difference in the world. With that in mind, here are two top healthcare actions to watch out for in the stock market today.

Health stocks to watch today

1. Pfizer (PFE stock)

The first standing Pfizer (PFE) is a pharmaceutical company. The Company is engaged in the development, manufacture and marketing of a wide variety of drugs. This includes prescription and over-the-counter medications. In addition, the Company’s major segments are Pharmaceuticals, Biologics & Vaccines, Consumer Healthcare and Animal Health. Additionally, the Company’s products include such well-known brands as Viagra, Lipitor and Advil.

PFE Recent Stock Market News

On Wednesday this week, Pfizer announced that it had completed the acquisition of the biotechnology company, Global Blood Therapeutics (NASDAQ: GBT). In detail, this acquisition will add a portfolio and pipeline of sickle cell disease (SCD) treatments for Pfizer. Most notably, is GBT’s Oxbryta® (voxelator). This is a first class drug that directly targets the root source of sickle cell disease. Also in the announcement, Pfizer completed the acquisition of GBT for $68.50 per share in cash, for a total projected enterprise value of nearly $5.4 billion.

Aamir Malik, Chief Business Innovation Officer, Executive Vice President of Pfizer, said: “With the talent, portfolio and pipeline of Global Blood Therapeutics now part of Pfizer, we look forward to accelerating innovation and rapidly bringing several potential first-in-class treatments to people with sickle cell disease.

PFE Stock Chart

During Thursday morning’s trading session, Pfizer stock is trading down 1.11% to $43.70 per share.

Source: TD Ameritrade Terms of Service

2. Regeneron Pharmaceuticals (REGN stock)

Next, Regeneron Pharmaceuticals (REGN) is a biopharmaceutical company that develops, manufactures and markets drugs for the treatment of serious diseases. Regeneron’s product portfolio includes therapies for eye disease, cancer, genetic disorders, inflammation and other conditions.

REGN Recent Stock Market News

On Tuesday this week, Regeneron announced that it will release its Q3 2022 financial and operating results on Thursday, November 3, the morning before the opening bell. In August, REGN released its second quarter 2022 financial results. Taking a dive, the company posted earnings of $9.77 per share in the second quarter of 2022 on revenue of $2.9 billion.

REGN Stock Chart

Year-to-date, REGN shares have outperformed the broader market, up 18% so far. Meanwhile, Thursday morning, Regeneron stock is trading at $741.33 per share.

REGN Stock Chart
Source: TD Ameritrade Terms of Service

If you enjoyed this article and want to learn how to trade so that you have the best chance of making a profit consistently, you need to check out this YouTube channel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


Comments are closed.